skip to content

Interim Results

Abbott Labs Q4 sales up

28 January 2016 12:56

Abbott Laboratories says fourth-quarter worldwide sales of USD5.2 billion increased 4.9 percent on an operational basis and decreased 3.1 percent on a reported basis.

Full-year sales increased 9.1 percent on an operational basis and 0.8 percent on a reported basis.

Full-year sales in emerging markets increased double digits excluding the impact of 2014 acquisitions and foreign exchange.

Adjusted diluted EPS from continuing operations, which excludes specified items, was USD0.62 in the fourth quarter and USD2.15 for the full year, at the midpoint of Abbott's previous guidance range and reflecting 8.6 percent growth for the full year.

Reported diluted EPS from continuing operations under GAAP was USD0.46 in the fourth quarter and USD1.72 for the full year.

"In 2015, we achieved top-tier sales and earnings growth despite a challenging currency environment," said Miles D. White, chairman and chief executive officer, Abbott. "Our underlying performance continues to be strong."

Story provided by StockMarketWire.com

Related Company: ABT

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.